Puja B. Parikh

Puja B. Parikh

Auto-generated profile, based on publicly available information

Puja B. Parikh

Department of Medicine, Stony Brook University Hospital, Stony Brook, New York.

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2018 in JACC
Verified
Journal Article
Closed access
RWRon Waksman
Ron Waksman
TRToby Rogers
Toby Rogers
RTRebecca Torguson
Rebecca Torguson
PGPaul Gordon
Paul Gordon
AEAfshin Ehsan
Afshin Ehsan
PCPaul J. Corso
Paul J. Corso

20 November 2018 in Biomechanics and Modeling in Mechanobiology
Verified
Journal Article
Closed access
PDF file
MBMatteo Bianchi
Matteo Bianchi
GMGil Marom
Gil Marom
RGRam P. Ghosh
Ram P. Ghosh
OROren M. Rotman
Oren M. Rotman
PPPuja Parikh
Puja Parikh
Danny BluesteinDanny Bluestein
Danny Bluestein

21 May 2024 in Circulation
Verified
Journal Article
Open access
AHAdrian F. Hernandez
Adrian F. Hernandez
JUJacob A. Udell
Jacob A. Udell
WJW. Schuyler Jones
W. Schuyler Jones
Stefan D. AnkerStefan D. Anker
Stefan D. Anker
MPMark C. Petrie
Mark C. Petrie
JBJaved Butler
Javed Butler
BACKGROUND: Empagliflozin reduces the risk of heart failure (HF) events in patients with type 2 diabetes at high cardiovascular risk, chronic kidney disease, or prevalent HF irrespective of ejection fraction. Whereas the EMPACT-MI trial (Effect of Empagliflozin on Hospitalization for Heart Failure and Mortality in Patients With Acute Myocardial Infarction) showed that empagliflozin does not reduce the risk of the composite of hospitalization for HF and all-cause death, the effect of empagliflozin on first and recurrent HF events after myocardial infarction is unknown. METHODS: EMPACT-MI was a double-blind, randomized, placebo-controlled, event-driven trial that randomized 6522 patients hospitalized for acute myocardial infarction at risk for HF on the basis of newly developed left ventricular ejection fraction of <45% or signs or symptoms of congestion to receive empagliflozin 10 mg daily or placebo within 14 days of admission. In prespecified secondary analyses, treatment groups were analyzed for HF outcomes. RESULTS: Over a median follow-up of 17.9 months, the risk for first HF hospitalization and total HF hospitalizations was significantly lower in the empagliflozin compared with the placebo group (118 [3.6%] versus 153 [4.7%] patients with events; hazard ratio, 0.77 [95% CI, 0.60, 0.98]; P =0.031, for first HF hospitalization; 148 versus 207 events; rate ratio, 0.67 [95% CI, 0.51, 0.89]; P =0.006, for total HF hospitalizations). Subgroup analysis showed consistency of empagliflozin benefit across clinically relevant patient subgroups for first and total HF hospitalizations. The need for new use of diuretics, renin-angiotensin modulators, or mineralocorticoid receptor antagonists after discharge was less in patients randomized to empagliflozin versus placebo (all P <0.05). CONCLUSIONS: Empagliflozin reduced the risk of HF in patients with left ventricular dysfunction or congestion after acute myocardial infarction. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04509674.

10 September 2002 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
HMHo-Sang Moon
Ho-Sang Moon
EJEric M. Jacobson
Eric M. Jacobson
SKSonya M. Khersonsky
Sonya M. Khersonsky
MLMichael R. Luzung
Michael R. Luzung
DWDaniel P. Walsh
Daniel P. Walsh
YCYoung-Tae Chang
Young-Tae Chang

16 June 2018 in Current Cardiology Reports
Verified
Journal Article
Closed access
PDF file
MLMatthew Liakos
Matthew Liakos
PPPuja B. Parikh
Puja B. Parikh

1 May 2019 in JACC: Cardiovascular Interventions
Verified
Journal Article
Closed access
RWRon Waksman
Ron Waksman
PCPaul J. Corso
Paul J. Corso
RTRebecca Torguson
Rebecca Torguson
PGPaul Gordon
Paul Gordon
AEAfshin Ehsan
Afshin Ehsan
TRToby Rogers
Toby Rogers